FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309156962> ?p ?o ?g. }

• W4309156962 endingPage "534" @default.
• W4309156962 startingPage "520" @default.
• W4309156962 abstract "Prevention of fatal side effects during cancer therapy of cancer patients with high-dosed pharmacological inhibitors is to date a major challenge. Moreover, the development of drug resistance poses severe problems for the treatment of patients with leukemia or solid tumors. Particularly drug-mediated dimerization of RAF kinases can be the cause of acquired resistance, also called paradoxical activation. In the present work we re-analyzed the effects of different tyrosine kinase inhibitors (TKIs) on the proliferation, metabolic activity, and survival of the Imatinib-resistant, KIT V560G, D816V-expressing human mast cell (MC) leukemia (MCL) cell line HMC-1.2. We observed that low concentrations of the TKIs Nilotinib and Ponatinib resulted in enhanced proliferation, suggesting paradoxical activation of the MAPK pathway. Indeed, these TKIs caused BRAF-CRAF dimerization, resulting in ERK1/2 activation. The combination of Ponatinib with the MEK inhibitor Trametinib, at nanomolar concentrations, effectively suppressed HMC-1.2 proliferation, metabolic activity, and induced apoptotic cell death. Effectiveness of this drug combination was recapitulated in the human KIT D816V MC line ROSAKIT D816V and in KIT D816V hematopoietic progenitors obtained from patient-derived induced pluripotent stem cells (iPS cells) and systemic mastocytosis patient samples. In conclusion, mutated KIT-driven Imatinib resistance and possible TKI-induced paradoxical activation can be efficiently overcome by a low concentration Ponatinib and Trametinib co-treatment, potentially reducing the negative side effects associated with MCL therapy." @default.
• W4309156962 created "2022-11-24" @default.
• W4309156962 creator A5004290451 @default.
• W4309156962 creator A5009814224 @default.
• W4309156962 creator A5015357112 @default.
• W4309156962 creator A5017262639 @default.
• W4309156962 creator A5023137678 @default.
• W4309156962 creator A5026019470 @default.
• W4309156962 creator A5040053640 @default.
• W4309156962 creator A5052133650 @default.
• W4309156962 creator A5061628504 @default.
• W4309156962 creator A5064006829 @default.
• W4309156962 creator A5067027024 @default.
• W4309156962 creator A5069334938 @default.
• W4309156962 creator A5073819334 @default.
• W4309156962 creator A5077386212 @default.
• W4309156962 creator A5080990916 @default.
• W4309156962 date "2022-11-30" @default.
• W4309156962 modified "2023-09-27" @default.
• W4309156962 title "Capitalizing on paradoxical activation of the mitogen‐activated protein kinase pathway for treatment of Imatinib‐resistant mast cell leukemia" @default.
• W4309156962 cites W1490956705 @default.
• W4309156962 cites W1596038553 @default.
• W4309156962 cites W1848470479 @default.
• W4309156962 cites W1979016878 @default.
• W4309156962 cites W1990011632 @default.
• W4309156962 cites W1994373703 @default.
• W4309156962 cites W2004295816 @default.
• W4309156962 cites W2032344621 @default.
• W4309156962 cites W2039429331 @default.
• W4309156962 cites W2050422354 @default.
• W4309156962 cites W2051165598 @default.
• W4309156962 cites W2058554042 @default.
• W4309156962 cites W2070861102 @default.
• W4309156962 cites W2083607012 @default.
• W4309156962 cites W2108244474 @default.
• W4309156962 cites W2110648386 @default.
• W4309156962 cites W2122549662 @default.
• W4309156962 cites W2127150495 @default.
• W4309156962 cites W2139464974 @default.
• W4309156962 cites W2152273695 @default.
• W4309156962 cites W2159989896 @default.
• W4309156962 cites W2163188200 @default.
• W4309156962 cites W2209596544 @default.
• W4309156962 cites W2320950260 @default.
• W4309156962 cites W2736420338 @default.
• W4309156962 cites W2772888029 @default.
• W4309156962 cites W2796604072 @default.
• W4309156962 cites W2802805088 @default.
• W4309156962 cites W2908990432 @default.
• W4309156962 cites W3117530054 @default.
• W4309156962 doi "https://doi.org/10.1002/hon.3100" @default.
• W4309156962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36383121" @default.
• W4309156962 hasPublicationYear "2022" @default.
• W4309156962 type Work @default.
• W4309156962 citedByCount "1" @default.
• W4309156962 countsByYear W43091569622023 @default.
• W4309156962 crossrefType "journal-article" @default.
• W4309156962 hasAuthorship W4309156962A5004290451 @default.
• W4309156962 hasAuthorship W4309156962A5009814224 @default.
• W4309156962 hasAuthorship W4309156962A5015357112 @default.
• W4309156962 hasAuthorship W4309156962A5017262639 @default.
• W4309156962 hasAuthorship W4309156962A5023137678 @default.
• W4309156962 hasAuthorship W4309156962A5026019470 @default.
• W4309156962 hasAuthorship W4309156962A5040053640 @default.
• W4309156962 hasAuthorship W4309156962A5052133650 @default.
• W4309156962 hasAuthorship W4309156962A5061628504 @default.
• W4309156962 hasAuthorship W4309156962A5064006829 @default.
• W4309156962 hasAuthorship W4309156962A5067027024 @default.
• W4309156962 hasAuthorship W4309156962A5069334938 @default.
• W4309156962 hasAuthorship W4309156962A5073819334 @default.
• W4309156962 hasAuthorship W4309156962A5077386212 @default.
• W4309156962 hasAuthorship W4309156962A5080990916 @default.
• W4309156962 hasBestOaLocation W43091569621 @default.
• W4309156962 hasConcept C126322002 @default.
• W4309156962 hasConcept C170493617 @default.
• W4309156962 hasConcept C184235292 @default.
• W4309156962 hasConcept C185592680 @default.
• W4309156962 hasConcept C203014093 @default.
• W4309156962 hasConcept C2777413986 @default.
• W4309156962 hasConcept C2777583451 @default.
• W4309156962 hasConcept C2778461978 @default.
• W4309156962 hasConcept C2778472372 @default.
• W4309156962 hasConcept C2778729363 @default.
• W4309156962 hasConcept C2780381907 @default.
• W4309156962 hasConcept C42362537 @default.
• W4309156962 hasConcept C502942594 @default.
• W4309156962 hasConcept C55493867 @default.
• W4309156962 hasConcept C57074206 @default.
• W4309156962 hasConcept C62112901 @default.
• W4309156962 hasConcept C71924100 @default.
• W4309156962 hasConcept C86803240 @default.
• W4309156962 hasConcept C95444343 @default.
• W4309156962 hasConcept C98274493 @default.
• W4309156962 hasConceptScore W4309156962C126322002 @default.
• W4309156962 hasConceptScore W4309156962C170493617 @default.
• W4309156962 hasConceptScore W4309156962C184235292 @default.
• W4309156962 hasConceptScore W4309156962C185592680 @default.
• W4309156962 hasConceptScore W4309156962C203014093 @default.

• next